NCT01246089

Ranibizumab for Myopic Neovascularization

Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Instituto de Olhos de Goiania · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Detailed description

Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months.

Conditions

• Myopic Choroidal Neovascularization

Interventions

Type	Name	Description
DRUG	ranibizumab injection	Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)

Timeline

• Start date: 2009-07-01
• Primary completion: 2014-10-01
• Completion: 2014-11-01
• First posted: 2010-11-23
• Last updated: 2014-01-01

Locations

1 site across 1 country: Brazil